Project: ProTIDol - Validation of an innovative therapeutic product for the management of primary chronic pain by limiting persistent inflammation and associated neuroinflammations.
Notice: Action 1.1.5 of the PO FESR SICILY 2014/2020.
Objectives and activities: The general objective of the research project is the development of a prototype of a product based on PEA oxazoline (PEAOxa), to be used to counteract persistent inflammation processes and neuroinflammation associated with chronic pain. PEAOxa is a natural molecule, inhibitor and modulator of the enzyme NAAA (N-acylethanolamine-hydrolyzing acid amidase), as well as an endogenous regulator of the endocannabinoid system. The molecule, protected with Epitech patent and with co-authors of the patent pertaining to the University of Messina, at an experimental level it is able to counteract the inflammatory processes associated with painful states and to antagonize neuroinflammation. In terms of social impact, the general objective of the project responds to the urgent need to have innovative tools able to combat persistent inflammation and pain with greater efficacy than available pharmacological therapies and with the best safety profiles.
The project is led by a partnership made up of:
- Epitech Group S.p.A. (Epitech, Lead Partner);
- University of Messina: Department of Chemical, Biological, Pharmaceutical and Environmental Sciences (Chibiofaram) and Department of Clinical and Experimental Medicine, c/o UOC of Neurology and Neuromuscular Diseases. (DMCS-ME).
- University of Catania: Department of Chemical Sciences (DSC-UniCt) and Department of Advanced Medical, Surgical and Technological Sciences "G.F. Ingrassia" c/o Neurological Clinic, Catania (DMCTA-CT).
Financial support received from the EU: €3,475,395.00